Picture of Power: Price Momentum Map Syntax

Stephen Stewart Author is a PRO memberHas Had Over 300 FollowersHas Been a Top Public ChartList for Over 2 years Rank: 5 Followers: 379 Votes: 340 Years Member: 10 Last Update: 27 November 2015, 16:32 Categories: Momentum Stocks


Trade what you see, not what you think. Train the Eye. Optimize the 'sweet spot' of price action.

'MAP SYNTAX', is a 'Performance Driven' Discretionary (vs. Black Box) proprietary research effort that focuses on finding the
best stocks the market has to offer. Using multiple time frames, 'MAP SYNTAX' is designed to identify the best candidates for
both long term price momentum investing and short term price 'thrusts' for swing trading. Optimize the 'Sweet Spot'.

All charts are strictly for educational purposes only. No investment decisions should be made based on the analysis here.
Momentum investing can lead to large losses. Very important to have a sound money management strategy.

Map Syntax & Stephen Stewart are not a registered investment adviser, investment advisory service, registered analyst,
or broker-dealer and does not advise specific advice on securities to anyone.


0000 ^^^ Map Syntax ^^^

In Map Syntax land, we care about VIOLENT price action and optimizing it. Thats it. Simple Simon

00/00 (Bias)

11/26: (Long Bias) BLUE
11/22: (Short Bias) ABY, SCTY
11/21: (Long Bias) XLRN
11/20: (Long Bias) CTMX

Price action goes into Map Syntax, answers come out. Listen to your MAPS.

When you master your craft (trading system) and can execute flawlessly - There is a price you pay - Work (trading) becomes boring.
However, the financial rewards become astronomical, just ask Tiger Woods or Roger Federer. ....And when you ask them how
they MASTERED THEIR 'CRAFT', they will tell you, it isnt the mechanics or system of their game that takes them to the top, but rather,
the six inches of space between their ears that they have learned to manage and master. Trading is no different. ~

0000 TSLA 2013 - Case Study - 'Model Analysis'

In my opinion, trading momentum is for the investor that wants to get paid right now. It is nothing more then participating in a trend. However,
momentum investing is 'NOT' a good 'risk/reward' trade. In fact it is risky because you are betting on other investors to keep buying in the face
of higher prices by chasing prices. We are trying to profit from investors' fear of 'MISSING THE MOVE'. However, you can manage this
risk well. How? Because you can always sell (if your wrong).

0001 CTMX

0001 KITE: 11.5M Float [Health-Biotech/CAR-T]

Kite is emerging not as a CAR-T company, but as an ENGINEERED T-CELL co. CARs, TCRs, gene editing, antibodies, and drugs... everything could
eventually be packaged into T cells, not just for oncology, but also for autoimmune diseases. Kite has key partnerships, the deepest pipeline, and
remains the only unencumbered co in the field. They own everything they have. (Maxim Research Note)

T cells are natural cells that are present in all humans and survey potential infections and contaminations. They permanently screen for non-self
intrusion in the body and when they detect an infection, they kill contaminated cells and start amplifying significantly until the infection is resolved.
T cells screen non-self intrusions in the body by a receptor called the T Cell Receptor or TCR. These specific killing and amplifying properties of
T cells are exploited by researchers to convert T cells into cancer killing machines. T cells are modified by genome engineering to give them new
properties. T cells will receive a Chimeric Antigen Receptor (CAR) that will specifically target a specific type of cancer in order to kill the cancer
cell and induce amplification. T cell CARs will therefore fight cancer cells as if they were an infection.

0002 EGRX: <8m Float

11/17: Awaiting approval of two products with December PDUFA dates: our rapidly infused bendamustine product, and our recently licensed
Docetaxel Injection Concentrate, Non-Alcohol Formula, which has the potential to be the first alcohol-free docetaxel formulation approved in the US
(PDUFA: Dec 26).

0002 GOOGL: IV & Earnings Ramp

Date ...........Qtr........EPS........Cons......Surprise.....Revs...............Cons.
10/22/15 ...Q315......$7.35........$7.21......+$0.14........$18.7B.........$18.53B
07/16/15 ...Q215......$6.99........$6.71......+$0.28........$17.7B.........$17.79B

Alphabet A target raised to $940 at MKM Partners -- Mobile search could accelerate growth for extended period. ($764) 11/11
Google target raised to $781 from $730 at Citigroup (622.36) 9/24
Google A target raised to $847 from $720 at JMP Securities 9/21
Goldman Sachs upgraded Google (NASDAQ: GOOG) (NASDAQ: GOOGL) from Neutral and added the stock to its Conviction Buy List.
Its price target was raised $800, suggesting potential return of 31%. 8/26

0003 BIDU

0005 GBT

0006 WTW: 70%+ Short Interest

0008 CIRCLES OF STIMULUS - Market Timing & Price Optimization.

Two times a day, Wall street delivers THRUST, BUST or STALL.
Use those KEY DECISION TIMES to identify and time THRUST as well as pick an ideal time to book gains or cut losses.
[NOTE: This is not day trading.]

MONEY MGMT = Position Size, Timing the Entry, Cutting Losses & Booking Gains
- One of the traders most important tools is Money Mgmt
- The worlds best traders recognize it as their most important key to success - NOT THE TRADING SYSTEM

This information is presented for education purposes only. StockCharts.com is not responsible for any comments, advice, or annotations presented on this page. Please review our Terms of Use for more details.